The End of Life for Patients with Acute Myeloid Leukemia (AML)- a Single Center Experience
Judy Foster(Harvard University), Karen K. Ballen(University of Virginia Health System), Andrew M. Brunner(Harvard University), Amir T. Fathi(University of Southern California), Gabriella Hobbs(Harvard University), Donna Neuberg(Otsuka (Japan)), Traci M. Blonquist(Harvard University), Areej El‐Jawahri(Massachusetts General Hospital), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Hossein Sadrzadeh(Boston University), Philip C. Amrein(Massachusetts General Hospital)
Cited by 4
Related Papers
Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer
|Science|2017|1.6k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k